Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 84 clinical trials
Imatinib in Acute Ischaemic Stroke

A clinical trial comparing treatment with Imatinib to placebo when administered within 8 hours of stroke onset for 6 days, in addition to conventional stroke treatment after acute ischaemic

  • 16 views
  • 25 Jan, 2021
  • 26 locations
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients 60 Years in Deep Molecular Response

administration (one month ON/one month OFF for the 1st year; one month ON/two months OFF for the 2nd year; one month ON/three months OFF for the 3rd year) (experimental arm). Imatinib (Glivec), or Nilotinib

nilotinib
kinase inhibitor
gleevec
imatinib
dasatinib
  • 3 views
  • 31 Jul, 2021
  • 1 location
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy

imatinib
interferon
remission
leukemia
  • 8 views
  • 07 Nov, 2020
  • 1 location
Positioning Imatinib for Pulmonary Arterial Hypertension

to pump blood through the lungs. While current treatments relieve some of the symptoms, they do not stop or reverse the disease in the affected blood vessels. Imatinib is a medicine licensed for some

  • 0 views
  • 14 Jun, 2021
  • 8 locations
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

imatinib (Glivec®) in pretreated Philadelphia chromosome- positive (Ph+)/BCR-ABL+ CML patients in chronic phase.

interferon
gleevec
philadelphia chromosome
imatinib
leukemia
  • 11 views
  • 07 Nov, 2020
  • 1 location
Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

The purpose of this study is to verify effect and tolerability of imatinib on pulmonary and skin fibrosis in patients affected by systemic sclerosis.

cyclophosphamide
immunosuppressive agents
fibrosis
imatinib
alveolitis
  • 33 views
  • 07 Nov, 2020
  • 1 location
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)

The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.

secondary acute myeloid leukemia
refractory acute myeloid leukemia (aml)
serum bilirubin level
mitoxantrone
  • 15 views
  • 07 Nov, 2020
  • 1 location
Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

less than 20%). The effectiveness of imatinib for hematologic responses in patients with Ph + (observed in phase I and II) led to its use in phase III trials in combination with chemotherapy. They saw

  • 103 views
  • 03 Feb, 2021
  • 112 locations
Safety Tolerability & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution

This is a randomised, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and PK of single and multiple inhaled doses of imatinib inhalation solution

  • 0 views
  • 05 Jun, 2021
  • 1 location
Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years

associated with imatinib or dasatinib has acceptable tolerability in elderly patients. To determine whether this association can increase the rate and quality of referrals to the results of the

  • 1 views
  • 28 Jan, 2021
  • 1 location